<DOC>
	<DOCNO>NCT01950611</DOCNO>
	<brief_summary>The clinical outcome relapse acute promyelocytic leukemia ( APL ) poor current standard care approach . Additionally , standard care warrant autologous stem cell transplant do molecular remission achieve . Unfortunately , majority patient afford procedure . We previously report clinical outcome relapse patient manage without stem cell transplant show event free survival 5 year less 35 % . Pre-clinical data report laboratory demonstrates significant synergy arsenic trioxide ( ATO ; accept standard care agent relapse APL ) Bortezomib ( proteasome inhibitor ) . We evaluate combination extensively in-vitro data accept oral presentation American Society Hematology ( ASH ) meeting 2011 . More recently also report potential mechanism synergy ( Poster ASH 2012 ) . We also mouse model data support finding . We plan move combination ATO base therapy combine Bortezomib Phase II clinical trial validate observation . The anticipated potential combination therapy less expensive , cost effective safe comparable clinical outcome treat expensive standard care include autologous stem cell transplant majority patient afford .</brief_summary>
	<brief_title>Proteasome Inhibition Acute Promyelocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>. Diagnosis relapse ( 15 ; 17 ) ( PMLRARα ) positive APL confirm reverse transcriptase polymerase chain reaction ( RTPCR ) . ii . Normal cardiac function normal electrocardiogram ( QTc le 500 msec ) within 48 hour study entry . iii . Patient guardian willing give inform consent / assent . Must psychiatric disorder ( ) would interfere consent , study participation , followup . iv . Patients may receive hydroxyurea , 48 hour less trans retnoic acid ( ATRA ) , 1 dose anthracycline still eligible participation study . v. Life expectancy least 2 week entry study . vi . No age limit entry study . vii . ECOG performance score 0 , 1 , 2. viii . Fertile patient must agree use effective barrier method contraception ( e.g. , latex condom , diaphragm , cervical cap ) avoid pregnancy therapy 3 year follow discontinuation therapy . ix . Have negative serum urine pregnancy test prior first dose therapeutic drug ( patient female childbearing potential ) . If breast feeding willing stop breast feeding . i. Intracranial bleed diagnosis . ii . ECOG performance score 3 . iii . Severe uncontrolled infection , fulminant sepsis diagnosis document pneumonia . iv . History cardiac arrhythmia ; symptomatic coronary heart disease ; uncontrollable arterial hypertension ( diastolic blood pressure &gt; 115 mm Hg ) ; severe psychiatric disease concomitant diseases comply criterion participation study . v. Acute hepatitis ( Bilirubin ≥ 5mg % liver enzymes ≥ 4 time laboratory normal value ) vi . Acute renal failure serum creatinine ≥ 2 mg % reversed hydration . vii . Patients suffer additional malignant tumor . No past history receive therapy another malignancy , apart squamous cell carcinoma basal cell carcinoma skin . viii . Pregnancy lactation . ix . Patients proven intolerance study drug x . Inability , miss willingness anticipate lack compliance PI participate study . Must severe concurrent disease and/or uncontrolled medical condition , , judgment investigator , could predispose patient unacceptable safety risk compromise compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>acute promyelocytic leukemia</keyword>
	<keyword>arsenic trioxide</keyword>
	<keyword>proteasome inhibition</keyword>
	<keyword>bortezomib</keyword>
</DOC>